No child should die from diabetes

Type 1 diabetes is a life-long, autoimmune condition caused by very little to no insulin production, which can lead to serious complications and premature death. Complications are especially prevalent in low- and middle-income countries, where access to insulin and type 1 diabetes care is limited.

Type 1 diabetes affects an estimated 1.2 million children and young people in low- and middle-income countries, and there are approximately 98,700 new diagnoses every year. Data for type 1 diabetes are scarce and likely underestimate its true burden.

People with type 1 diabetes rely on daily insulin injections to survive, and managing the disease can be challenging for both the child and their family. However, with proper treatment, education and support, children with type 1 diabetes can thrive and live healthy lives.

The ambition of the Changing Diabetes® in Children partnership is that no child should die from diabetes.

Programme highlights*

More than

180,000 patient education sessions

52,249 children and young adults reached

25,000 healthcare professionals trained in the diagnosis and management of type 1 diabetes in children

400 clinics established or refurbished

*Tresor has type 1 diabetes and lives in Côte d’Ivoire

A complex disease requiring comprehensive care

Type 1 diabetes is a complex disease that requires careful management and continuous care. Changing Diabetes® in Children provides a holistic system of care built around four components of comprehensive diabetes care.

Ensuring comprehensive patient education:
Patient education is critical to the successful management of diabetes.

Strengthening the health workforce:
A misdiagnosis or delayed diagnosis of diabetes can result in the death of a child with diabetes.

Establishing a network of clinic facilities:
Children living with type 1 diabetes require accessible health facilities for regular check-ups and care.

Ensuring access to insulin and supplies:
The only effective treatment for type 1 diabetes is insulin, administered by injection.
A partnership model to support local healthcare systems

Changing Diabetes® in Children is led by four global partners: Novo Nordisk, Roche, the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the World Diabetes Foundation (WDF). The partnership takes a sustainable approach and relies on local cooperation from ministries of health, implementing partners and academic institutions. Academic institutions are involved in developing evidence, sharing learnings and creating digital solutions for programme delivery.

Changing Diabetes® in Children has the ambition to reach 100,000 children living with type 1 diabetes by 2030.

References
9. (IDF) IDF. Data from: New cases of type 1 diabetes (0-19 y), in 1000s. 2021.